A short total synthesis of the indolopyridine alkaloids angustine (1) and angustoline (2) has been achieved in five and six steps, respectively. Two key steps for assembly of the pentacyclic core included a Bischler-Napieralski cyclization and a cobalt-catalyzed carbonylative lactamization. A late-stage Mukaiyama hydration allowed the first successful transformation of angustine (1) to angustoline (2). (C) 2020 Published by Elsevier Ltd.
Regioselective syntheses of the indolopyridine alkaloids nauclefine, angustine, dihydroangustine and naucletine from a common intermediate
作者:Rodolfo Lavilla、Francisco Gallón、Joan Bosch
DOI:10.1039/c39950001675
日期:——
A short, flexible route for the synthesis of the title indolopyridine alkaloids consisting of the cyclization of enamide 3, followed by introduction of the requisite pyridine substituent by Pd0-catalysed reactions from the resulting pentacyclic bromo intermediate 4 is reported.
acetyl chloride induced cyclization of bromoenamide 10 affords the pentacyclic derivative 12 with high yield and regioselectivity. From this common synthetic intermediate, palladium-catalyzed reactions allow the total synthesis of indolopyridine alkaloids 1–6.
Synthesis of naucléfine, angustidine, angustine, and (±)-13b, 14-dihydroangustine
作者:David B. Repke、Jahangir Jahangir、Robin D. Clark、David B. MacLean
DOI:10.1039/c39880000439
日期:——
4-b]indolium trifluoromethanesulphonate reacts with the lithio derivatives of 3-cyano-4-methylpyridines to generate pentacyclic amidines which, upon hydrolysis and oxidation, produce naucléfine, angustine, and angustidine.
2,9-双-(三甲基甲硅烷基)-3,4-二氢吡啶并[3,4- b ]三氟甲磺酸吲哚鎓与3-氰基-4-甲基吡啶的硫醇衍生物反应生成五环am,该五环upon经水解和氧化后生成核苷,阿古斯丁和阿古斯丁。
Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
申请人:DermBiont, Inc.
公开号:US11040077B2
公开(公告)日:2021-06-22
Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.